Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Liver function changes after transarterial chemoembolization in US hepatocellular carcinoma patients: the LiverT study

Fig. 1

Proportion of patients with acute and chronic liver function deterioration after TACE compared to baseline (primary analysis). Acute period, 0–29 days after TACE; chronic period, 30–90 days after TACE. Deterioration thresholds: bilirubin increase of ≥ 50%, albumin decrease by 0.3 g/dL, AST increase of > 25%, ALT increase of > 25%, INR increase of ≥ 25%, all compared with baseline. ALT alanine transaminase, AST aspartate transaminase, CI confidence interval, INR international normalized ratio, TACE transarterial chemoembolization

Back to article page
\